Thursday, October 8, 2026
688 articles scanned · 10 high-signal
Washington is turning policy design into balance-sheet risk, as eligibility rules, audits and drug-price interventions shift financial exposure onto plans, providers and manufacturers just as the quality agenda pivots from measurement to proof of outcomes.